Mesalazine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Mesalazine

Examples of brand names: Salofalk [DE]

ATC code: A07EC02

Main use (for orientation): Inflammatory bowel disease

Documented research summary

CBD-rich extract was studied during stable 5-ASA therapy, without a positive primary remission effect. New pilot study: only 2/14 participants continued oral 5-ASA; the investigational preparation was CBD plus sodium propionate as an enema. Both papers provide co-medication context, not an isolated mesalazine interaction; evidence for an isolated pair finding is classified as insufficient.

Uncertainties and limitations

The pilot study does not allow specific safety assessment of the two 5-ASA co-medications; do not attribute group results to those two patients. CBD extract, CBD/propionate and CBD isolate are not identical. Missing data do not establish safety.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD-rich botanical extract; also contains THC – insufficient evidence

Finding ID: B0444

Type of result: Co-medication context; negative primary efficacy endpoint

Observation: Primary remission endpoint not positive (28% versus 26%); extract less well tolerated than placebo.

Mechanism: Additional extract therapy for ulcerative colitis during stable 5-ASA treatment

Study type: Randomised controlled adjunctive-treatment study; not an isolated interaction study

Context studied: Ten-week study of CBD-rich, THC-containing extract added to stable 5-ASA therapy.

Clinical interpretation: Documented co-medication context; insufficient evidence for an isolated mesalazine–cannabinoid pair and not proof of general safety.

Limitations and uncertainties: No isolated mesalazine pharmacokinetics or attribution of adverse events to a causal mesalazine–cannabinoid interaction. Extract is not CBD isolate; the abstract does not individually specify 5-ASA preparations for all participants.

Original sources for this finding: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. [VE_MED_29538683]

CBD (synthetic; combined with sodium propionate in the investigational preparation) – insufficient evidence

Finding ID: B0445

Type of result: Co-medication context; no isolatable pair finding

Observation: Only 2 of 14 participants continued oral 5-ASA. The published group results do not allow separate assessment of this combination.

Mechanism: Local CBD/propionate preparation in refractory distal colitis; not interaction pharmacokinetics

Study type: Uncontrolled pilot study

Context studied: Enema contained CBD 60 mg plus sodium propionate 70 mg per 50 ml; 12 weeks, 9 complete follow-ups. Details describe the study, not use instructions.

Clinical interpretation: Documented research context only; not clinical pair evidence.

Limitations and uncertainties: No control group, second active investigational component, little 5-ASA co-medication; no independent mesalazine interaction or safety conclusion. Methods/tables/results read.

Original sources for this finding: Safety and Preliminary Clinical Outcomes of a Combined Cannabidiol and Sodium Propionate Enema in Refractory Ulcerative Proctitis: An Open-Label Pilot Study. [VE_MED_42578019]

References and access status

[VE_LABEL_D0280] APRISO (MESALAMINE) CAPSULE, EXTENDED RELEASE [SALIX PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VE_MED_29538683] A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis.

Original source / bibliographic reference

Authors: Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C, Lindsay JO, Taylor A, Barron R, Wright S.

Year: 2018

Source type: Research Support, Non-U.S. Gov't; Multicenter Study; Randomized Controlled Trial; Journal Article

DOI: 10.1093/ibd/izy002

PMID: 29538683

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[VE_MED_42578019] Safety and Preliminary Clinical Outcomes of a Combined Cannabidiol and Sodium Propionate Enema in Refractory Ulcerative Proctitis: An Open-Label Pilot Study.

Original source / bibliographic reference

Authors: Naftali T, Stein A, Kayless H, Prutchi Sagiv S.

Year: 2026

Source type: research-article; Journal Article

DOI: 10.1159/000552842

PMID: 42578019

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility